ReShape Lifesciences Set to Host Key Stockholders Meeting Soon
The Board of Directors of ReShape Lifesciences Inc. has unanimously endorsed a strategy that centers around pivotal mergers and asset transitions that are designed to bolster the company’s future. On the proposed agenda, the shareholders are encouraged to express their votes in favor of key proposals that will significantly shape the company’s next chapter.
Important Details of the Special Meeting
ReShape Lifesciences (NASDAQ: RSLS), a leader in physician-led weight loss and metabolic health solutions, is organizing a Special Meeting of Stockholders on July 24, with plans to conduct the meeting at 11:30 AM ET. During this meeting, stockholders will have the opportunity to vote on critical proposals including a merger with Vyome Therapeutics, a company dedicated to addressing immune-inflammatory and rare diseases. This merger, coupled with asset sales to Biorad Medisys, represents a strategic move aimed at maximizing shareholder value.
Significance of Shareholder Participation
In an address to shareholders, Paul F. Hickey, the President and CEO of ReShape Lifesciences, emphasized the importance of each vote, regardless of the number of shares held. The potential transformation brought about by the approval of the merger agreement with Vyome and the concurrent asset sale is viewed as a necessary step towards advancing ReShape as a frontrunner in the health solutions market. Hickey urged shareholders to vote in favor of the proposals, which include the issuance of new stock, the authorized sale of company assets, and amendments to the company’s certificate of incorporation.
Understanding the Merger and Its Benefits
The planned merger with Vyome Therapeutics is anticipated to unlock new avenues for growth by enhancing the company’s portfolio with cutting-edge immunology products. Venkat Nelabhotla, Vyome's CEO, has articulated that this partnership is pivotal for the speed and efficacy of therapies that cater to chronic immune issues. This merger also positions Vyome for success in public markets post-merger, with an emphasis on merging innovations from both India and the U.S.
Proposals for the Vote
The stockholder meeting will revolve around three primary proposals:
- The issuance of shares of common stock related to the merger.
- The sale of substantial assets to Biorad Medisys.
- Amendments to the certificate of incorporation for a revised Board structure post-merger.
Stockholders are encouraged to cast their votes and reflect on the significance of their involvement in steering the direction of the company through this critical juncture.
How to Participate in the Voting Process
Shareholders who have not yet participated in the voting process are urged to do so swiftly. Voting can conveniently be done via telephone or online, adhering to the instructions outlined on previously sent proxy cards or forms. For assistance with the voting process, shareholders may reach out to Innisfree M&A Incorporated, the proxy solicitor, at a toll-free number for guidance.
Engaging with the ReShape Lifesciences Team
For additional information or queries regarding the voting process, the Investor Relations team is available to assist. Paul F. Hickey is open to discussions and can be reached directly for inquiries regarding stockholder matters.
About ReShape Lifesciences®
ReShape Lifesciences continues to pave the way in the field of weight loss and metabolic health solutions, offering an array of FDA-approved products aimed at effectively managing and treating obesity. The company is committed to innovation, providing solutions such as the Lap-Band® System and the investigational Diabetes Bloc-Stim Neuromodulation™ (DBSN™) system. As it focuses on expansion and enhanced shareholder value, ReShape Lifesciences remains dedicated to delivering results and improving patient outcomes.
Frequently Asked Questions
What is the purpose of the Special Meeting of Stockholders?
The meeting is convened to discuss and vote on important proposals regarding the merger with Vyome Therapeutics and asset sale to Biorad Medisys.
When will the Special Meeting take place?
The Special Meeting is scheduled for July 24, at 11:30 AM ET.
How can shareholders cast their votes?
Voting can be done via phone or the Internet by following the instructions provided on the proxy card sent to shareholders.
What are the main proposals being voted on?
Shareholders will vote on the issuance of common stock, the sale of assets, and amendments to the certificate of incorporation.
Who should I contact for more information?
For any questions, shareholders should reach out to Paul F. Hickey, the CEO of ReShape Lifesciences, or the proxy solicitor Innisfree M&A Incorporated.
